ডেনমার্ক -
ডেনিশ -
Lægemiddelstyrelsen (Danish Medicines Agency)
viacoram 3,5+2,5 mg tabletter
les laboratoires servier - amlodipin, perindoprilarginin - tabletter - 3,5+2,5 mg
ইউরোপীয় ইউনিয়ন -
ডেনিশ -
EMA (European Medicines Agency)
valdoxan
les laboratoires servier - agomelatin - depressiv lidelse, major
ইউরোপীয় ইউনিয়ন -
ডেনিশ -
EMA (European Medicines Agency)
thymanax
les laboratoires servier - agomelatin - depressiv lidelse, major
ডেনমার্ক -
ডেনিশ -
Lægemiddelstyrelsen (Danish Medicines Agency)
libroxar 2+0,5 mg resoribletter, sublinguale
laboratoires smb s.a. - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 2+0,5 mg
ডেনমার্ক -
ডেনিশ -
Lægemiddelstyrelsen (Danish Medicines Agency)
libroxar 8+2 mg resoribletter, sublinguale
laboratoires smb s.a. - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 8+2 mg
ডেনমার্ক -
ডেনিশ -
Lægemiddelstyrelsen (Danish Medicines Agency)
fixopost 50 mikrogram/ml+5 mg/ml øjendråber, opløsning
laboratoires thea s.a.s. - latanoprost, timololmaleat - øjendråber, opløsning - 50 mikrogram/ml+5 mg/ml
ইউরোপীয় ইউনিয়ন -
ডেনিশ -
EMA (European Medicines Agency)
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
ডেনমার্ক -
ডেনিশ -
Lægemiddelstyrelsen (Danish Medicines Agency)
elymbus 0,1 mg/g øjengel, enkeltdosisbeholder
laboratoires thea s.a.s. - bimatoprost - øjengel, enkeltdosisbeholder - 0,1 mg/g
ইউরোপীয় ইউনিয়ন -
ডেনিশ -
EMA (European Medicines Agency)
clopidogrel bgr (previously zylagren)
biogaran - clopidogrel (as hydrogen sulfate) - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - forebyggelse af atherothrombotic begivenheder clopidogrel er indiceret i:voksne patienter med myokardieinfarkt (fra få dage, indtil der er mindre end 35 dage), iskæmisk slagtilfælde (fra 7 dage indtil mindre end 6 måneder) eller etableret perifer arteriel sygdom.
ইউরোপীয় ইউনিয়ন -
ডেনিশ -
EMA (European Medicines Agency)
savene
clinigen healthcare b.v. - dexrazoxanhydrochlorid - ekstravasation af diagnostiske og terapeutiske materialer - alle andre terapeutiske produkter - savene er indiceret til behandling af anthracyclin-ekstravasation.